testing. Further, the invention rat has a longer life span so that studies of longer duration or studies involving serial sampling can be conducted. The invention rat can be used to evaluate potential treatments for AD and to further investigate AD physiology.

Potential Commercial Applications:

• In vivo validation of AD therapeutics.

• Development and validation of imaging methods to diagnose AD.

• Detailed investigation of AD pathology and physiology.

Competitive Advantages:

• Rat model in contrast to available mice models.

• Rat model based on over-expression of genes responsible for early onset AD.

Development Stage:

• Prototype.

• In vivo data available (animal).

Inventors: Robert M. Cohen, et al. (NIMH).

Publication: Borchelt DR, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1–42/1–40 ratio in vitro and in vivo. Neuron. 1996 Nov; 17(5):1005–13. [PMID 8938131]

Intellectual Property: HHS Reference No. E–211–2012/0—Research Tool. Patent protection is not being pursued for this technology.

Licensing Contact: Lauren Nguyen-Antczak, Ph.D., J.D.; 301–435–4074; *nguyenantczakla@mail.nih.gov*.

Prognostic Biomarkers for Patients With Early Stage Lung Cancer

Description of Technology: Investigators at the National Cancer Institute have discovered a set of biomarkers that can identify patients with early stage lung cancer who have a high risk of relapse. Available for licensing are prognostic assays based on these biomarkers, which can enable clinicians to select more effective therapy and post-operative follow-up strategies.

Surgery is the standard care for patients with stage I lung cancer. Despite successful surgery, 20–30% of patients will relapse. Chemotherapy can improve patient survival; however, it is controversial if early stage cancer patients should be treated with chemotherapy since, for many cases, it will harm quality of life with little therapeutic benefit. Utilizing patient samples, the investigators conducted a retrospective study in eight patient cohorts that validated the gene classifier set. These prognostic methods can guide physicians to select appropriate treatment and follow-up while sparing other patients of unnecessary treatment and negative side-effects of chemotherapy.

Potential Commercial Applications:

• Method to determine the prognosis of patients with lung cancer.

• Method to select more effective treatment and post-operative follow-up for patients with early stage lung cancer.

Competitive Advantages: Assays were validated in human tissue samples and eight different patient cohorts.

Development Stage:

• Early-stage.

• In vivo data available (human).

Inventors: Curt Harris (NCI), Aaron Schetter (NCI), Ichiro Akagi (Nippon Medical School), and Hirokazu Okayama (Fukushima Medical University).

Publication: Akagi I, et al. Combination of protein coding and non-coding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. Cancer Res. 2013 May 2; Epub ahead of print. [PMID 23639940]

Intellectual Property: HHS Reference No. E–048–2012/0—U.S. Provisional Application No. 61/691,118 filed 20 Aug 2012.

Related Technology: HHS Reference No. E–181–2006/0—U.S. Patent Nos. 7,943,318 and 8,377,637 and Australian Patent No. 2007205234, and related patent applications pending in Australia, Canada, China, Europe, Japan and the U.S.

Licensing Contact: Jennifer Wong, M.S.; 301–435–4633; *wongje@mail.nih.gov*.

Collaborative Research Opportunity: The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize an early detection test for lung cancer. For collaboration opportunities, please contact John Hewes, Ph.D. at *hewesj@mail.nih.gov*.

Retroviral and Lentiviral Vectors To Increase Efficiency of Inducible Pluripotent Stem Cell (iPSC) Production

Description of Technology: Researchers at the National Cancer Institute have discovered that modulating a specific p53 isoform increases the number of inducible pluripotent stem cells that can be obtained from cells that are being re-programmed to obtain pluripotent cells. It is known that the activity of p53 regulates the self-renewal and pluripotency of normal and cancer stem cells, and also affects re-programming efficiency of iPS cells. This p53 isoform-based technology provides a more natural process of increasing iPS cell production than previous methods of decreasing p53.

Potential Commercial Applications:

• Stem cell-based regenerative medicine.

• Cancer therapeutic that targets cancer stem cells.

Competitive Advantages: The retroviral and lentiviral vectors in this invention allow more selective control of p53 activities than siRNA or mutant p53 methods.

Development Stage: Early-stage.

Inventors: Curtis C. Harris (NCI) et al.

Intellectual Property: HHS Reference No. E–239–2010/0—

• U.S. Provisional Patent Application No. 61/389,134 filed 01 Oct 2010.

• International Patent Application PCT/US2011/054304 filed 30 Sep 2011, which published as WO/2012/044979 on 05 Apr 2012.

• Australian Patent Application 2011308567 filed 30 Sep 2011.

• US Patent Application No. 13/877,100 filed 29 Mar 2013.

• Applications also pending in CA, EP, JP (filing nos. unknown).

Related Technologies:

• HHS Reference No. E–033–2008/0—Therapeutic Applications of a p53 Isoform in Regenerative Medicine, Aging, and Cancer.

• HHS Reference No. E–137–2010/0—Research Tool. Patent protection is not being pursued for this technology.

Licensing Contact: Patrick McCue, Ph.D.; 301–435–5560; *mccuepat@mail.nih.gov*.

Collaborative Research Opportunity: The National Cancer Institute, Laboratory of Human Carcinogenesis, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Retroviral and Lentiviral Vectors. For collaboration opportunities, please contact John D. Hewes, Ph.D. at *hewesj@mail.nih.gov*.

Dated: June 20, 2013.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2013–15204 Filed 6–25–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel; Review of Applications on HIV–AIDS/Alcohol Comparative Effectiveness & Implementation Research (RFA AA 13–003, 004).

Date: July 30–31, 2013.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: NIAAA, 5635 Fishers Lane, Rockville, MD 20852 (Virtual Meeting).

Contact Person: Ranga Srinivas, Ph.D., Chief, Extramural Project Review Branch EPRB, NIAAA, National Institutes of Health, 5365 Fishers Lane, Room 2085, Rockville, MD 20852 (301) 451–2067, *srinivar @mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program No. 93.273, Alcohol Research Programs; National Institutes of Health, HHS)

Dated: June 19, 2013.

Carolyn A. Baum,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–15203 Filed 6–25–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Dermatology.

Date: July 22, 2013.

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Daniel F McDonald, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4110, MSC 7814, Bethesda, MD 20892, (301) 435–1215, *mcdonald@csr.nih.gov*.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Psychological Health, Development and Aging.

Date: July 22, 2013.

Time: 2:30 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Dana Jeffrey Plude, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3176, MSC 7848, Bethesda, MD 20892, 301–435–2309, *pluded@csr.nih.gov*.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Pilot Clinical Studies in Nephrology and Urology.

Date: July 23–24, 2013.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Atul Sahai, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2188, MSC 7818, Bethesda, MD 20892, 301–435–1198, *sahaia@csr.nih.gov*.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Translational Research in Diabetes and Obesity.

Date: July 24, 2013.

Time: 10:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Robert Garofalo, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institute of Health, 6701 Rockledge Drive, Room 6156, MSC 7892, Bethesda, MD 20892, 301–435–1043, *garofalors@csr.nih.gov*.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Mental Disorders and Addiction.

Date: July 24, 2013.

Time: 2:00 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Jay Joshi, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5196, MSC 7846, Bethesda, MD 20892, (301) 408–9135, *joshij@csr.nih.gov*.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Biodemography of Aging.

Date: July 24, 2013.

Time: 12:30 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Suzanne Ryan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3139, MSC 7770, Bethesda, MD 20892, (301) 435–1712, *ryansj@csr.nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: June 20, 2013.

Carolyn A. Baum,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–15198 Filed 6–25–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Orthopedic and Skeletal Biology.

Date: July 8–9, 2013.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Contact Person: Baljit S Moonga, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4214, MSC 7806, Bethesda, MD 20892, 301–435–1777, *moongabs@mail.nih.gov.*